Nasdaq8d
Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook
Foghorn Therapeutics Inc. announced continued enrollment in its Phase 1 trial for FHD-909, a first-in-class oral selective SMARCA2 inhibitor targeting SMARCA4 mutated cancers, particularly non ...
Hosted on MSN3mon
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527
“These findings confirm our hypothesis that a selective and potent CDK9 inhibitor offers meaningful ... With a focus on its SMARCA degrader programs, Prelude intends to seek a partner for ...